Peter DeMuth

Company: Elicio Therapeutics

Job title: Chief Scientific Officer

Seminars:

Unveiling the Potential of RAS-Targeted Vaccines as a Durable & Versatile Immunotherapy Solution 11:45 am

• How to elicit robust immune responses against KRAS with vaccination formats? • How to enhance the action of key immune cells and generate robust tumor-specific immune responses? • What challenges need to be overcome to expand development of vaccines for more complex cancers?Read more

day: Day One Track A AM